No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Truetide said on Wednesday that its wholly-owned subsidiary Paraytec had launched a focused development programme aimed at establishing a high-throughput, real-time fluorescent assay to study alpha-synuclein fibril formation, targeting a key bottleneck in Parkinson's disease drug discovery.
The AIM-traded firm, formerly known as Braveheart Investment Group, said Paraytec was developing the assay using its CX300 detection system, with the aim of enabling rapid, accurate and cost-effective screening of compounds that could prevent or reverse pathological alpha-synuclein aggregation.
It said the aggregation of alpha-synuclein was widely regarded as a central pathological process in Parkinson's disease and related neurodegenerative disorders, and the absence of robust screening tools has been a barrier to the development of disease-modifying therapies.
The planned work would include the production and purification of recombinant wild-type and pathogenic mutant alpha-synuclein proteins, the optimisation of site-specific fluorescent labelling compatible with real-time measurement on the CX300 platform, and the full validation of the assay across multiple alpha-synuclein variants.
Paraytec also intended to prepare a technical methods paper and present the results at leading international synucleinopathy conferences in 2026, in collaboration with professor Oliver Bandmann of the Sheffield Institute for Translational Neuroscience.
If successful, Truetide said Paraytec expected to own a proprietary assay not currently available from any commercial provider in a format optimised for the CX300 system.
The directors believed the assay could become a preferred screening tool for pharmaceutical and biotechnology companies active in neurodegenerative disease research, with potential commercialisation routes including reagent kit sales, fee-for-service screening and strategic partnerships.
"Paraytec remains close to making the scientific and commercial breakthrough via its CX300 technology, that the directors of Truetide hope for," said chief executive Trevor Brown.
"Although somewhat protracted, the development work for a rapid Gram test continues, this new program to establish a high-throughput, real-time fluorescent assay for alpha-synuclein fibril formation significantly increases Paraytec's exposure to the possibility of eventual commercialisation of the CX300."
Truetide said it would provide a further update once the development programme had been completed and validation data had been published.
At 1407 GMT, shares in Truetide were up 34.88% at 2.9p.
Reporting by Josh White for Sharecast.com.